dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Esindaja nimetamine

Sotsiaalministeerium · 19. jaanuar 2021
Viit
1.4-2/178-1
Registreeritud
19. jaanuar 2021
Dokumendi liik
Sissetulev kiri
Adressaat
EV Alaline esindus EL juures
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2021
Vastutaja
Hanna Alajõe (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Euroopa Liidu ja väliskoostöö osakond)
Lahendamise tähtaeg
18. veebruar 2021

Failid

  • 📎56-annex_a.pdf65 KB
  • 📎56-edastamismeil.msg690 KB
  • 📎56.pdf304 KB
  • 📎E-kiri.pdf117 KB

Sisu (failidest)

ANNEX A Representatives nominated by Estonia Mandate Nomination Name Membership Expiry Date Due Date Committee on Orphan Medicinal Products (COMP) Vallo Tillmann Member 17 May 2021 17 March 2021 Mandates will be presumed to take effect the day following expiry of the current mandate unless otherwise indicated. Nominations for CHMP and CVMP representatives are subject to appropriate consultation of the European Medicines Agency's Management Board in accordance with Article 61 of Regulation (EC) no. 726/2004. # Classified as confidential by the European Medicines Agency Page 2 of 2 Saatja: Obon Roger <[email protected]> Saaja: Esindus EL juures üldaadress, Nominations Teema: Estonia - 2021-01-13 - Nomination invitation for COMP member For the attention of HE Mr Aivo Orav, Your Excellency, Please find attached a letter from the Executive Director of the European Medicines Agency regarding the nomination of representatives in the Committee for Orphan Medicinal Products (COMP). Kind regards, Roger Obon Experts and Declarations of Interests Management Meeting Secretariat Office Committees and Quality Assurance Department European Medicines Agency Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands Telephone +31 (0)88 781 6763 [email protected]<mailto:[email protected]> | www.ema.europa.eu<https://www.ema.europa.eu/en> | For directions, see How to find us<https://www.ema.europa.eu/en/about-us/contact/how-find-us> Follow us: [cid:[email protected]] [cid:[email protected]] [cid:[email protected]] This message and any attachment contain information which may be confidential or otherwise protected from disclosure. It is intended for the addressee(s) only and should not be relied upon as legal advice unless it is otherwise stated. If you are not the intended recipient(s) (or authorised by an addressee who received this message), access to this e-mail, or any disclosure or copying of its contents, or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you have received this e-mail in error, please inform the sender immediately. P Please consider the environment before printing this e-mail Classified as confidential by the European Medicines Agency ________________________________________________________________________ This e-mail has been scanned for all known viruses by European Medicines Agency. ________________________________________________________________________ HE Mr Aivo Orav Permanent Representation of Estonia to the European Union Rue Guimard 11-13 B-1040 Brussels BELGIUM 13 January 2021 EMA/19244/2021 Executive Director Your Excellency, Subject: Nomination of representatives in the Committee for Orphan Medicinal Products (COMP) The European Medicines Agency was established by Regulation (EC) No 726/2004. Members and alternates of the Agency’s Management Board and scientific committees are nominated for a three- year mandate by EU member states and EEA-EFTA countries. The three-year mandate of the representative listed in Annex A is due to expire. I, therefore, invite you to nominate representative for a new three-year mandate starting 18/05/2021. In case you are nominating new representative and a different start date for the mandate is envisaged, please inform me accordingly. If no nomination for representatives is received by the end date of the current mandate, the positions will be considered vacant for a three-year period or until a nomination is received. In making your nominations, please note that the Agency’s Management Board has determined that members of scientific committees should meet conditions concerning their declarations of interests as described in the Policy on the handling of competing interests of scientific committees’ members and experts. This policy can be found on the EMA website. I would like to draw your attention to the attached Annex B, which lists the recommended criteria for experience and expertise of COMP members and alternates for consideration when nominating a new representative. As agreed with the network of the Heads of Medicines Agencies in order to address the increasing complexity in scientific developments related to the committee’s activities, the current expertise of the committee and the expertise required for upcoming procedures are monitored. It would be appreciated if the following specific areas of expertise that were identified as desirable for the current and upcoming work of the committee, could be taken into consideration when nominating a new representative, subject to the availability of such expertise to the relevant competent authority in your country: Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. • Statistics (medical statistician) • Clinical specialist in: − Skin disorders (dermatologist) − Infectious diseases • Genetics An overview of the current composition of the Committee and the expertise of its members is attached for your information. Please address the nominations to my attention at PO Box 71010, 1008 BA Amsterdam, The Netherlands, indicating full contact details for the nominees and the start date of the mandate, together with any additional information you believe may assist these nominations. In case you have already posted me your nominations, I kindly ask you to disregard this correspondence. A copy of this letter will be forwarded to the head of the relevant competent authority in your country. Yours faithfully, Emer Cooke Digitally signed by Emer Cooke Date: 2021.01.15 20:10:14 +01'00' Emer Cooke Executive Director Encs: Annex A Annex B Current COMP composition and expertise EMA/19244/2021 Page 2/2 Saatja: Webdesktop <[email protected]> Saadetud: 18.01.2021 18:35 Adressaat: SM Info <[email protected]>; info ravimiamet ee <[email protected]>; <[email protected]>; Elen Ohov <[email protected]> Koopia: <[email protected]> Teema: Webdesktop: Kiri nr 14-4/56 / Esindaja nimetamine Euroopa Ravimiameti harvikravimite komiteesse (COMP) Tere!Edastan Euroopa Ravimiameti kirja. Palun andke enne 17.03.2021 EV AEEL-le teada ([email protected], cc: [email protected]), kas me pikendame praeguse liikme Vallo Tillmanni mandaati või nimetame uue.Reg. number: 14-4/56Reg. kuupäev: 18.01.2021Sisu: Letter from the Executive Director of the European Medicines Agency regarding the nomination of representatives in the Committee for Orphan Medicinal Products (COMP).Heade soovidegaTiiu [email protected]är EV AEEL juures*** TÄHELEPANU *** See e-kiri (kaasa arvatud manused) on mõeldud ainult e-kirja adressaatidele ning võib sisaldada ametialaseks kasutamiseks ettenähtud teavet. Teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mistahes viisil kõrvaliletse isikutele avaldadauJ .hul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, palun teavitage sellest kohe saatjat ning kustutage e-kiri oma arvutist.*** ATTENTION *** This e-mail and its attachments may contain official information. If you are not the intended recipient, please notify the sender immediately, delete this e-mail and destroy any copies. Any dissemination or use of this information by a person other than the intended recipient is unauthorized and may be unlawful.
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel